American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility

Mark E. Robson, Angela R. Bradbury, Banu Arun, Susan M. Domchek, James M. Ford, Heather L. Hampel, Stephen M. Lipkin, Sapna Syngal, Dana S. Wollins, Noralane Morey Lindor

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively parallel sequencing-also known as next-generation sequencing-to cancer susceptibility testing. This technology introduces a new level of complexity into the practice of cancer risk assessment and management, requiring renewed effort on the part of ASCO to ensure that those providing care to patients with cancer receive the necessary education to use this new technology in the most effective, beneficial manner. The purpose of this statement is to explore the challenges of new and emerging technologies in cancer genetics and provide recommendations to ensure their optimal deployment in oncology practice. Specifically, the statement makes recommendations in the following areas: germline implications of somatic mutation profiling, multigene panel testing for cancer susceptibility, quality assurance in genetic testing, education of oncology professionals, and access to cancer genetic services.

Original languageEnglish (US)
Pages (from-to)3660-3667
Number of pages8
JournalJournal of Clinical Oncology
Volume33
Issue number31
DOIs
StatePublished - Nov 1 2015

Fingerprint

Medical Oncology
Genetic Testing
Neoplasms
Technology
Genetic Services
High-Throughput Nucleotide Sequencing
Ethics Committees
Professional Education
Risk Management
Patient Care
Education
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

American society of clinical oncology policy statement update : Genetic and genomic testing for cancer susceptibility. / Robson, Mark E.; Bradbury, Angela R.; Arun, Banu; Domchek, Susan M.; Ford, James M.; Hampel, Heather L.; Lipkin, Stephen M.; Syngal, Sapna; Wollins, Dana S.; Lindor, Noralane Morey.

In: Journal of Clinical Oncology, Vol. 33, No. 31, 01.11.2015, p. 3660-3667.

Research output: Contribution to journalArticle

Robson, ME, Bradbury, AR, Arun, B, Domchek, SM, Ford, JM, Hampel, HL, Lipkin, SM, Syngal, S, Wollins, DS & Lindor, NM 2015, 'American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility', Journal of Clinical Oncology, vol. 33, no. 31, pp. 3660-3667. https://doi.org/10.1200/JCO.2015.63.0996
Robson, Mark E. ; Bradbury, Angela R. ; Arun, Banu ; Domchek, Susan M. ; Ford, James M. ; Hampel, Heather L. ; Lipkin, Stephen M. ; Syngal, Sapna ; Wollins, Dana S. ; Lindor, Noralane Morey. / American society of clinical oncology policy statement update : Genetic and genomic testing for cancer susceptibility. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 31. pp. 3660-3667.
@article{c29b717f5a5148e1801f63f3121f00e5,
title = "American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility",
abstract = "The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively parallel sequencing-also known as next-generation sequencing-to cancer susceptibility testing. This technology introduces a new level of complexity into the practice of cancer risk assessment and management, requiring renewed effort on the part of ASCO to ensure that those providing care to patients with cancer receive the necessary education to use this new technology in the most effective, beneficial manner. The purpose of this statement is to explore the challenges of new and emerging technologies in cancer genetics and provide recommendations to ensure their optimal deployment in oncology practice. Specifically, the statement makes recommendations in the following areas: germline implications of somatic mutation profiling, multigene panel testing for cancer susceptibility, quality assurance in genetic testing, education of oncology professionals, and access to cancer genetic services.",
author = "Robson, {Mark E.} and Bradbury, {Angela R.} and Banu Arun and Domchek, {Susan M.} and Ford, {James M.} and Hampel, {Heather L.} and Lipkin, {Stephen M.} and Sapna Syngal and Wollins, {Dana S.} and Lindor, {Noralane Morey}",
year = "2015",
month = "11",
day = "1",
doi = "10.1200/JCO.2015.63.0996",
language = "English (US)",
volume = "33",
pages = "3660--3667",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - American society of clinical oncology policy statement update

T2 - Genetic and genomic testing for cancer susceptibility

AU - Robson, Mark E.

AU - Bradbury, Angela R.

AU - Arun, Banu

AU - Domchek, Susan M.

AU - Ford, James M.

AU - Hampel, Heather L.

AU - Lipkin, Stephen M.

AU - Syngal, Sapna

AU - Wollins, Dana S.

AU - Lindor, Noralane Morey

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively parallel sequencing-also known as next-generation sequencing-to cancer susceptibility testing. This technology introduces a new level of complexity into the practice of cancer risk assessment and management, requiring renewed effort on the part of ASCO to ensure that those providing care to patients with cancer receive the necessary education to use this new technology in the most effective, beneficial manner. The purpose of this statement is to explore the challenges of new and emerging technologies in cancer genetics and provide recommendations to ensure their optimal deployment in oncology practice. Specifically, the statement makes recommendations in the following areas: germline implications of somatic mutation profiling, multigene panel testing for cancer susceptibility, quality assurance in genetic testing, education of oncology professionals, and access to cancer genetic services.

AB - The American Society of Clinical Oncology (ASCO) has long affirmed that the recognition and management of individuals with an inherited susceptibility to cancer are core elements of oncology care. ASCO released its first statement on genetic testing in 1996 and updated that statement in 2003 and 2010 in response to developments in the field. In 2014, the Cancer Prevention and Ethics Committees of ASCO commissioned another update to reflect the impact of advances in this area on oncology practice. In particular, there was an interest in addressing the opportunities and challenges arising from the application of massively parallel sequencing-also known as next-generation sequencing-to cancer susceptibility testing. This technology introduces a new level of complexity into the practice of cancer risk assessment and management, requiring renewed effort on the part of ASCO to ensure that those providing care to patients with cancer receive the necessary education to use this new technology in the most effective, beneficial manner. The purpose of this statement is to explore the challenges of new and emerging technologies in cancer genetics and provide recommendations to ensure their optimal deployment in oncology practice. Specifically, the statement makes recommendations in the following areas: germline implications of somatic mutation profiling, multigene panel testing for cancer susceptibility, quality assurance in genetic testing, education of oncology professionals, and access to cancer genetic services.

UR - http://www.scopus.com/inward/record.url?scp=84947279527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947279527&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.63.0996

DO - 10.1200/JCO.2015.63.0996

M3 - Article

C2 - 26324357

AN - SCOPUS:84947279527

VL - 33

SP - 3660

EP - 3667

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -